BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company's platforms use computational and synthetic biology and research from Doctors Rotem Sorek, Eran Elinav, and Eran Segal of the Weizmann Institute of Science and Doctor Timothy K. Lu of the Massachusetts Institute of Technology.